{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:32Z","timestamp":1790915012233,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.dld.2018.09.013","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T12:58:56Z","timestamp":1537793936000},"page":"689-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study"],"prefix":"10.1016","volume":"51","author":[{"given":"Nicole","family":"Brighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-7630","authenticated-orcid":false,"given":"Giuseppe","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Manuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-7402","authenticated-orcid":false,"given":"Andrea","family":"Lisotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Abbondanza","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dld.2018.09.013_bib0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jhep.2016.03.005","article-title":"EASL clinical practice guidelines on the prevention, diagnosis and treatment of gallstones","volume":"65","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2018.09.013_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy \u2014 biotherapy and novel targeted agents","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2018.09.013_bib0015","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"28","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2018.09.013_bib0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.dld.2018.09.013_bib0025","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","article-title":"Adverse events associated with somatostatin analogs in acromegaly","volume":"14","author":"Grasso","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.dld.2018.09.013_bib0030","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogues on glucose homeostasis: a meta-analysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.dld.2018.09.013_bib0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/ENDO:20:3:299","article-title":"Comparison of efficacy and tolerability of somatostatin analogues and other therapies for acromegaly","volume":"20","author":"Burt","year":"2003","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.dld.2018.09.013_bib0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03346419","article-title":"Somatostatin analogues and gallstones: a retrospective survey on a large series of acromegalic patients","volume":"31","author":"Attanasio","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.dld.2018.09.013_bib0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2265.2007.02811.x","article-title":"Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems","volume":"66","author":"Paisley","year":"2007","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.dld.2018.09.013_bib0050","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00268-010-0428-1","article-title":"Prophylactic cholecystectomy in midgut carcinoid patients","volume":"34","author":"Norlen","year":"2010","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.dld.2018.09.013_bib0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#","article-title":"Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors","volume":"79","author":"Trendle","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.dld.2018.09.013_bib0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2036.2001.00924.x","article-title":"Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR","volume":"15","author":"Moschetta","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dld.2018.09.013_bib0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/gut.2004.048074","article-title":"Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones","volume":"54","author":"Hofmann","year":"2005","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dld.2018.09.013_bib0070","first-page":"154","article-title":"Ileal resection-induced gallstones: altered bilirubin or cholesterol metabolism?","volume":"96","author":"Pitt","year":"1984","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.dld.2018.09.013_bib0075","first-page":"18","article-title":"Biliary cholesterol and lithogeneity of bile in patients after ileal resection","volume":"104","author":"Farkkila","year":"1988","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2018.09.013_bib0080","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hep.1840210309","article-title":"The natural history of gallstones: the GREPCO experience. The GREPCO Group","volume":"21","author":"Attili","year":"1995","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2018.09.013_bib0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1245\/s10434-017-6093-y","article-title":"Prophylactic cholecystectomy at time of surgery for small bowel neuroendocrine tumor does not increase postoperative morbidity","volume":"25","author":"Sinnamon","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.dld.2018.09.013_bib0090","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ijsu.2014.10.006","article-title":"Different setups of laparoscopic cholecystectomy: conversion and complication rates: a retrospective cohort study","volume":"12","author":"Kais","year":"2014","journal-title":"Int J Surg"},{"issue":"4","key":"10.1016\/j.dld.2018.09.013_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s005350300071","article-title":"Secondary hemocholecyst after radiofrequency ablation therapy for hepatocellular carcinoma","volume":"38","author":"Yamamoto","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2018.09.013_bib0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1440-1746.2007.05078.x","article-title":"Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single-center experience","volume":"23","author":"Chen","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2018.09.013_bib0105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2214\/ajr.180.3.1800697","article-title":"Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety","volume":"180","author":"Chopra","year":"2003","journal-title":"Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.dld.2018.09.013_bib0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2006.02450.x","article-title":"Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly","volume":"64","author":"Caron","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.dld.2018.09.013_bib0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","article-title":"Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly","volume":"157","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.dld.2018.09.013_bib0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865818309836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:10:02Z","timestamp":1761624602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865818309836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1590865818309836"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.013","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2018.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}